Maya Ivan D, Carlton Donna, Estrada Erin, Allon Michael
Division of Nephrology, University of Alabama at Birmingham, AL, USA.
Am J Kidney Dis. 2007 Aug;50(2):289-95. doi: 10.1053/j.ajkd.2007.04.014.
Dialysis catheter-related bacteremia is often treated successfully by instilling an antibiotic-heparin solution into the catheter lumen (an antibiotic lock) in conjunction with systemic antibiotic therapy without removal of the catheter. The efficacy of this therapy is uncertain in Staphylococcus aureus bacteremia.
Quality improvement report.
SETTING & PARTICIPANTS: 113 catheter-dependent hemodialysis outpatients with S aureus catheter-related bacteremia treated with a standardized antibiotic lock protocol. Data for all patients with catheter-related bacteremia are recorded in a prospective database.
In conjunction with systemic antibiotic therapy (vancomycin for methicillin-resistant S aureus or cefazolin for methicillin-sensitive S aureus), an antibiotic lock was instilled into each catheter lumen after each dialysis session for 3 weeks.
Treatment failure is defined as persistent fever after 48 hours of antibiotic therapy or recurrent S aureus bacteremia within 90 days. Clinical cure is defined as resolution of fever and no recurrence of bacteremia. Major infection-related complications within 6 months were documented.
The catheter could not be salvaged in 67 patients (59%) because of persistent fever in 40 patients and recurrent bacteremia in 27 patients. A clinical cure was achieved in 46 patients (41%). A serious complication of catheter-related bacteremia occurred in 9.7% of all patients (11 of 113 patients). Serious complications were observed in 25% of patients (10 of 40 patients) with persistent fever, but only 1.4% of all other patients (1 of 73 patients; P < 0.0001).
This was a single-center study. Serum antibiotic levels were not measured.
Routine antibiotic lock therapy is not appropriate for patients with S aureus catheter-related bacteremia. Serious complications occur primarily in patients with persistent fever.
透析导管相关菌血症通常通过在全身抗生素治疗的同时向导管腔内注入抗生素 - 肝素溶液(抗生素封管)来成功治疗,而无需拔除导管。这种疗法在金黄色葡萄球菌菌血症中的疗效尚不确定。
质量改进报告。
113例依赖导管的血液透析门诊患者,患有金黄色葡萄球菌导管相关菌血症,接受标准化抗生素封管方案治疗。所有导管相关菌血症患者的数据记录在一个前瞻性数据库中。
在全身抗生素治疗(耐甲氧西林金黄色葡萄球菌用万古霉素,甲氧西林敏感金黄色葡萄球菌用头孢唑林)的同时,每次透析后向每个导管腔内注入抗生素封管液,持续3周。
治疗失败定义为抗生素治疗48小时后持续发热或90天内复发性金黄色葡萄球菌菌血症。临床治愈定义为发热消退且无菌血症复发。记录6个月内主要的感染相关并发症。
67例患者(59%)的导管无法挽救,原因是40例患者持续发热,27例患者复发性菌血症。46例患者(41%)实现了临床治愈。所有患者中有9.7%(113例中的11例)发生了严重的导管相关菌血症并发症。持续发热的患者中有25%(40例中的10例)观察到严重并发症,但其他所有患者中只有1.4%(73例中的1例;P<0.0001)。
这是一项单中心研究。未测量血清抗生素水平。
常规抗生素封管疗法不适用于金黄色葡萄球菌导管相关菌血症患者。严重并发症主要发生在持续发热的患者中。